[Skip to Content]
[Skip to Content Landing]
Views 1,522
Citations 0
Clinical Trials Update
November 27, 2018

Artificial Pancreas Improves Glycemic Control

JAMA. 2018;320(20):2068. doi:10.1001/jama.2018.18512

Hybrid closed-loop insulin delivery provided better glucose control than sensor-augmented pump therapy with less risk of hypoglycemia in patients with suboptimally controlled type 1 diabetes, reported a Lancetstudy. Sensor-augmented pump therapy transmits glucose readings to the patient, who then makes decisions about insulin dosing. Hybrid closed-loop artificial pancreas systems use an algorithm to automate insulin delivery while giving patients some control.